Our COVID-19 Vaccine Study – What’s Next?

COVID-19 SCIENTIFIC RESOURCES

Our Science
COVID-19 SCIENTIFIC RESOURCES
COVID-19 SCIENTIFIC RESOURCES

COVID-19 SCIENTIFIC RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

COVID-19 CLINICAL TRIAL RESULTS

Our Science
Covid Update
Covid Updates

COVID-19 CLINICAL TRIAL RESULTS

Updates on our COVID-19 clinical trial.

VISIT OUR COVID-19 HUB

Your Health
GettyImages-1208505315_790x500.png
GettyImages-1208505315_1000x450_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

THE ANTIGEN: #COVID19 PODCAST

Podcasts
the_antigen_image_380x700.png
the_antigen_image_1000x450.jpg

THE ANTIGEN: #COVID19 PODCAST

Season 2 of The Antigen podcast focuses on COVID-19, Pfizer’s response to the crisis and more.

Cancer Screening: Get it Done

Your Health
cancer_screening_get_it_done_790x500.png
cancer_screening_get_it_done_1000x450.jpg

Cancer Screening: Get it Done

A new initiative encourages people to speak with their doctor about keeping up with cancer screenings & follow-up appointments, where it’s safe to do so, during the COVID-19 pandemic.

Latest News

– If approved, marstacimab has potential to be a best-in-class treatment option among novel non-factor agents – Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors. BASIS is a global Phase 3, open-label, multicenter study that will evaluate annualized bleed…